Medpace (MEDP) to Release Quarterly Earnings on Monday

Medpace (NASDAQ:MEDP) will likely be releasing its Q4 2025 results after the market closes on Monday, February 9th. Analysts expect Medpace to post earnings of $4.18 per share and revenue of $689.5330 million for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, February 10, 2026 at 9:00 AM ET.

Medpace Stock Down 1.8%

Shares of Medpace stock opened at $582.48 on Monday. The business has a fifty day simple moving average of $584.28 and a 200-day simple moving average of $532.38. The firm has a market cap of $16.41 billion, a price-to-earnings ratio of 40.73, a price-to-earnings-growth ratio of 1.96 and a beta of 1.42. Medpace has a fifty-two week low of $250.05 and a fifty-two week high of $628.92.

Insider Activity

In other Medpace news, CEO August J. Troendle sold 668 shares of the firm’s stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $590.69, for a total transaction of $394,580.92. Following the completion of the sale, the chief executive officer directly owned 646,184 shares in the company, valued at approximately $381,694,426.96. This trade represents a 0.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Kevin M. Brady sold 3,000 shares of Medpace stock in a transaction dated Friday, November 21st. The shares were sold at an average price of $590.35, for a total value of $1,771,050.00. Following the transaction, the chief financial officer directly owned 6,000 shares in the company, valued at approximately $3,542,100. This trade represents a 33.33% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 341,695 shares of company stock worth $205,718,239 over the last quarter. Corporate insiders own 20.30% of the company’s stock.

Institutional Trading of Medpace

Several institutional investors have recently made changes to their positions in MEDP. AQR Capital Management LLC boosted its holdings in shares of Medpace by 65.1% during the 3rd quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock worth $518,170,000 after buying an additional 404,226 shares during the period. Arrowstreet Capital Limited Partnership lifted its position in Medpace by 205.8% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock worth $161,523,000 after acquiring an additional 211,411 shares during the last quarter. Wasatch Advisors LP boosted its holdings in Medpace by 14.0% during the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock valued at $296,853,000 after acquiring an additional 116,354 shares during the period. Invesco Ltd. grew its position in shares of Medpace by 18.9% in the third quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock valued at $276,313,000 after purchasing an additional 85,517 shares during the last quarter. Finally, Qube Research & Technologies Ltd increased its stake in shares of Medpace by 1,527.8% in the third quarter. Qube Research & Technologies Ltd now owns 74,780 shares of the company’s stock worth $38,449,000 after purchasing an additional 70,186 shares during the period. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

MEDP has been the subject of several research reports. Weiss Ratings restated a “buy (b)” rating on shares of Medpace in a research report on Wednesday. Truist Financial set a $555.00 target price on shares of Medpace in a report on Monday, October 27th. Barclays lifted their price target on shares of Medpace from $485.00 to $525.00 and gave the stock an “underweight” rating in a research report on Monday, December 15th. Mizuho set a $660.00 price objective on Medpace in a research report on Friday, January 9th. Finally, Robert W. Baird set a $613.00 price objective on Medpace in a research note on Friday, October 24th. Two equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, Medpace presently has an average rating of “Reduce” and an average price target of $491.27.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.